MX346206B - Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. - Google Patents
Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.Info
- Publication number
- MX346206B MX346206B MX2014000373A MX2014000373A MX346206B MX 346206 B MX346206 B MX 346206B MX 2014000373 A MX2014000373 A MX 2014000373A MX 2014000373 A MX2014000373 A MX 2014000373A MX 346206 B MX346206 B MX 346206B
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- group
- virus
- philogenetic
- viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161572417P | 2011-07-14 | 2011-07-14 | |
| EP11173953 | 2011-07-14 | ||
| PCT/EP2012/063637 WO2013007770A1 (en) | 2011-07-14 | 2012-07-12 | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000373A MX2014000373A (es) | 2014-03-31 |
| MX346206B true MX346206B (es) | 2017-03-09 |
Family
ID=47505543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000373A MX346206B (es) | 2011-07-14 | 2012-07-12 | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8961978B2 (enExample) |
| EP (1) | EP2731967B1 (enExample) |
| JP (1) | JP5683752B2 (enExample) |
| KR (1) | KR101941724B1 (enExample) |
| CN (1) | CN103906763B (enExample) |
| AU (1) | AU2012282504B2 (enExample) |
| BR (1) | BR112014000263B1 (enExample) |
| CA (1) | CA2838999C (enExample) |
| DK (1) | DK2731967T3 (enExample) |
| EA (1) | EA027054B1 (enExample) |
| ES (1) | ES2608321T3 (enExample) |
| HR (1) | HRP20161740T1 (enExample) |
| IL (1) | IL230222A (enExample) |
| IN (1) | IN2014CN00953A (enExample) |
| MX (1) | MX346206B (enExample) |
| MY (1) | MY166282A (enExample) |
| PH (1) | PH12013502479A1 (enExample) |
| WO (1) | WO2013007770A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2731967B1 (en) | 2011-07-14 | 2016-10-12 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| IN2014CN04742A (enExample) | 2011-11-28 | 2015-09-18 | Crucell Holland Bv | |
| MX367743B (es) | 2011-12-05 | 2019-09-04 | Trellis Bioscience Llc | Anticuerpos utiles para la inmunizacion pasiva de influenza. |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US9649375B2 (en) | 2013-03-14 | 2017-05-16 | The Administrators Of The Tulane Educational Fund | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
| IL241552B2 (en) * | 2013-03-14 | 2023-09-01 | Contrafect Corp | Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| CN105452270B (zh) | 2013-05-30 | 2020-12-01 | 扬森疫苗与预防公司 | 流行性感冒病毒疫苗及其用途 |
| SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| RU2682049C2 (ru) * | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | Лечение вируса гриппа а h7n9 |
| AU2015214146B2 (en) * | 2014-02-04 | 2020-09-17 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| MX2016012530A (es) | 2014-03-27 | 2017-01-05 | Genentech Inc | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso. |
| KR101628331B1 (ko) * | 2014-03-28 | 2016-06-08 | 주식회사 녹십자엠에스 | 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법 |
| WO2016005480A1 (en) | 2014-07-10 | 2016-01-14 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
| KR102463632B1 (ko) | 2014-07-10 | 2022-11-03 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 백신 및 이의 용도 |
| WO2016011035A2 (en) * | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| CA2975655C (en) * | 2015-02-05 | 2023-09-19 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
| US10174127B2 (en) | 2015-02-05 | 2019-01-08 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza neuraminidase |
| US11135282B2 (en) * | 2015-04-08 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| AU2016261299B2 (en) | 2015-05-11 | 2019-12-05 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing peptidomimetic compounds |
| WO2016200543A2 (en) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-inluenza antibodies and methods of use thereof |
| MX389708B (es) | 2015-06-01 | 2025-03-20 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| JP2019502715A (ja) | 2016-01-13 | 2019-01-31 | メディミューン，エルエルシー | Ａ型インフルエンザを治療する方法 |
| CA3015347A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| US10703803B2 (en) | 2016-03-01 | 2020-07-07 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza B neuraminidase |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2018038096A1 (ja) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | モノクローナル抗体又はその抗原結合フラグメント及びその使用 |
| JP2020500169A (ja) | 2016-10-27 | 2020-01-09 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | インフルエンザウイルスを中和する化合物 |
| CA3051377A1 (en) | 2017-01-27 | 2018-08-02 | National Research Council Of Canada | Hemagglutinin-specific antibodies and uses thereof |
| WO2018141854A1 (en) | 2017-02-02 | 2018-08-09 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
| US11040963B2 (en) | 2017-02-02 | 2021-06-22 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibitions |
| TW201837170A (zh) | 2017-02-28 | 2018-10-16 | 賓州大學委員會 | 新穎ａａｖ媒介的流感疫苗 |
| RS65241B1 (sr) | 2017-02-28 | 2024-03-29 | Univ Pennsylvania | Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| PL3743106T3 (pl) | 2018-01-23 | 2022-11-14 | Janssen Vaccines & Prevention B.V. | Szczepionki przeciwko wirusowi grypy i ich zastosowanie |
| SG11202006379UA (en) | 2018-01-26 | 2020-07-29 | Regeneron Pharma | Human antibodies to influenza hemagglutinin |
| EP3946613A1 (en) | 2019-03-25 | 2022-02-09 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| JP7865873B2 (ja) | 2019-09-05 | 2026-05-26 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | インフルエンザウイルスワクチン及びその使用 |
| WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
| US11175293B1 (en) | 2021-01-04 | 2021-11-16 | University Of Utah Research Foundation | Rapid assay for detection of SARS-CoV-2 antibodies |
| US20240043416A1 (en) | 2021-02-04 | 2024-02-08 | Sichuan Haisco Pharmaceutical Co., Ltd. | Salt and crystal form of ha inhibitor compound |
| EP4508077A4 (en) * | 2022-04-14 | 2026-03-25 | Invisishield Tech Ltd | COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS |
| US20260183380A1 (en) | 2022-11-14 | 2026-07-02 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| TW202527960A (zh) | 2023-09-06 | 2025-07-16 | 美商賽諾菲巴斯德公司 | 經修飾ｂ型流感血球凝集素多肽及核酸及其用途 |
| WO2026022067A1 (en) | 2024-07-20 | 2026-01-29 | Leyden Laboratories B.V. | Neutralising antibodies against influenza viruses |
| WO2026027730A1 (en) | 2024-07-31 | 2026-02-05 | Sanofi | Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof |
| WO2026052773A1 (en) | 2024-09-06 | 2026-03-12 | Sanofi | Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| EP0934526B1 (en) | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| ES2378272T3 (es) | 1999-04-15 | 2012-04-10 | Crucell Holland B.V. | Producción de proteína recombinante en una célula humana |
| US7329530B2 (en) | 2001-06-15 | 2008-02-12 | Crucell Holland B.V. | Chimaeric phages |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| FR2921928B1 (fr) | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
| CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| EP2168987A1 (en) * | 2008-09-22 | 2010-03-31 | Mucosis B.V. | Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain |
| KR101790354B1 (ko) | 2009-05-11 | 2017-10-25 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도 |
| EP2731967B1 (en) | 2011-07-14 | 2016-10-12 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
-
2012
- 2012-07-12 EP EP12735516.2A patent/EP2731967B1/en active Active
- 2012-07-12 AU AU2012282504A patent/AU2012282504B2/en active Active
- 2012-07-12 US US14/126,404 patent/US8961978B2/en active Active
- 2012-07-12 HR HRP20161740TT patent/HRP20161740T1/hr unknown
- 2012-07-12 ES ES12735516.2T patent/ES2608321T3/es active Active
- 2012-07-12 MY MYPI2014700068A patent/MY166282A/en unknown
- 2012-07-12 CN CN201280034558.0A patent/CN103906763B/zh active Active
- 2012-07-12 BR BR112014000263-0A patent/BR112014000263B1/pt active IP Right Grant
- 2012-07-12 MX MX2014000373A patent/MX346206B/es active IP Right Grant
- 2012-07-12 WO PCT/EP2012/063637 patent/WO2013007770A1/en not_active Ceased
- 2012-07-12 CA CA2838999A patent/CA2838999C/en active Active
- 2012-07-12 EA EA201490288A patent/EA027054B1/ru not_active IP Right Cessation
- 2012-07-12 DK DK12735516.2T patent/DK2731967T3/en active
- 2012-07-12 PH PH1/2013/502479A patent/PH12013502479A1/en unknown
- 2012-07-12 JP JP2014519551A patent/JP5683752B2/ja active Active
- 2012-07-12 KR KR1020137035132A patent/KR101941724B1/ko active Active
- 2012-07-12 IN IN953CHN2014 patent/IN2014CN00953A/en unknown
-
2013
- 2013-12-29 IL IL230222A patent/IL230222A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/597,016 patent/US9593159B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2731967T3 (en) | 2017-01-16 |
| US20150274811A1 (en) | 2015-10-01 |
| EP2731967B1 (en) | 2016-10-12 |
| EA027054B1 (ru) | 2017-06-30 |
| BR112014000263A2 (pt) | 2017-02-14 |
| ES2608321T3 (es) | 2017-04-07 |
| CA2838999A1 (en) | 2013-01-17 |
| PH12013502479A1 (en) | 2014-01-20 |
| MY166282A (en) | 2018-06-25 |
| EA201490288A1 (ru) | 2014-05-30 |
| NZ618530A (en) | 2016-05-27 |
| KR20140095017A (ko) | 2014-07-31 |
| AU2012282504B2 (en) | 2017-07-20 |
| CN103906763A (zh) | 2014-07-02 |
| US9593159B2 (en) | 2017-03-14 |
| AU2012282504A1 (en) | 2014-02-06 |
| CN103906763B (zh) | 2016-10-12 |
| WO2013007770A1 (en) | 2013-01-17 |
| JP5683752B2 (ja) | 2015-03-11 |
| BR112014000263B1 (pt) | 2022-01-18 |
| CA2838999C (en) | 2021-02-16 |
| MX2014000373A (es) | 2014-03-31 |
| IL230222A (en) | 2017-09-28 |
| IN2014CN00953A (enExample) | 2015-04-10 |
| HRP20161740T1 (hr) | 2017-02-10 |
| EP2731967A1 (en) | 2014-05-21 |
| US20140120113A1 (en) | 2014-05-01 |
| JP2014527403A (ja) | 2014-10-16 |
| KR101941724B1 (ko) | 2019-01-23 |
| US8961978B2 (en) | 2015-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014000373A (es) | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y el virus de influenza b. | |
| MX360056B (es) | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. | |
| MX2011011331A (es) | Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas. | |
| CY1124043T1 (el) | Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων | |
| MX2014000749A (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| MD20140035A2 (ro) | Metodă de tratament al hepatitei virale C | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| EA201590890A1 (ru) | Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| MY175708A (en) | Dna antibody constructs and method of using same | |
| EA201590731A1 (ru) | Антитела к гемагглютинину и способы применения | |
| MX391043B (es) | Formulaciones de anticuerpo y metodos. | |
| CL2017002082A1 (es) | Nuevas proteínas especificas para pioverdina y pioquelina | |
| BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
| EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
| MX350282B (es) | Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas. | |
| EA201500854A1 (ru) | Композиция, содержащая по меньшей мере две связывающие молекулы, нейтрализующие вирус гриппа а | |
| MX376962B (es) | Nuevos compuestos macrociclicos. | |
| MX378749B (es) | Agentes para neutralizacion de influenza. | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| PE20170185A1 (es) | Composiciones farmaceuticas para tratar enfermedades infecciosas | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| CU20140006A7 (es) | Moléculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenético 1 y grupo filogenético 2 y virus de la influenza b | |
| EA201500143A1 (ru) | Терапия макулярной дегенерации на основе баклофена и акампросата |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |